Charles River Laboratories

M-Files Leverages Automation and AI to Revolutionize the Workplace in 2023

Retrieved on: 
Thursday, March 7, 2024
Software, Technology, Artificial Intelligence, Data Management, Cloud, Acquisition, MENT, Collection, CRL, DocuSign, AI, ROI, Culture, Information Today, Growth, Charles River Laboratories, Microsoft Outlook, ARR, Centaur, Gold, Metadata, Business, Automation, Knowledge, Silver, Microsoft, Business intelligence, Information technology, Online shopping

“Automation is critical to ensure the productivity of knowledge workers,” said Antti Nivala, founder and CEO, M-Files.

Key Points: 
  • “Automation is critical to ensure the productivity of knowledge workers,” said Antti Nivala, founder and CEO, M-Files.
  • By creating a new work paradigm with knowledge work automation, we remove the challenge of sorting through information manually, simplifying daily tasks and increasing productivity.
  • In 2023 among the first in our market, M-Files enhanced its knowledge work automation platform with generative AI capabilities to revolutionize the way knowledge workers automate their processes - from document creation and management to workflow automation, external collaboration, enterprise search, security, compliance, and audit trails.
  • In 2023, M-Files expanded its offering with next-generation, no-code document automation capabilities through its acquisition of Ment and integration into the M-Files platform.

B&C and Acta Announce Appointment of Mark J. Washko as Senior Government Affairs Advisor, and Alexander E. Howard and Michelle C. Mims to Science Team Positions

Retrieved on: 
Friday, March 1, 2024
National Association, Reno 1868 FC, Commerce, Molecular biology, Consultant, University, ASTM, House, Biophysical chemistry, Energy, EPA, Legislation, Public policy, Representative, Good laboratory practice, Advisory board, Committee, Environmental justice, Federation, College, Bowling Green State University, Quality assurance, Corteva, Majority, Biophysical environment, BASF, Environment, OECD, Business network, TSCA, Sunscreen Innovation Act, Charles River Laboratories, Government, Organization, GLP, Frank, Bachelor, Society, B&C, Policy, American Chemistry Council, Management

WASHINGTON, March 1, 2024 /PRNewswire-PRWeb/ -- Bergeson & Campbell, P.C. (B&C®) and The Acta Group (Acta®) are pleased to announce the appointment of several professionals to key roles at our firms.

Key Points: 
  • (B&C®) and The Acta Group (Acta®) are pleased to announce the appointment of Mark J. Washko, Alexander E. Howard, and Michelle C. Mims to key roles at our firms.
  • (B&C®) and The Acta Group (Acta®) are pleased to announce the appointment of several professionals to key roles at our firms.
  • Mr. Washko, Mr. Howard, and Ms. Mims join a powerful team of advocates, scientists, and regulatory and business consultants at B&C and Acta.
  • Mr. Washko, Mr. Howard, and Ms. Mims join a powerful team of advocates, scientists, and regulatory and business consultants at B&C and Acta.

Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use

Retrieved on: 
Thursday, February 29, 2024
Investigational New Drug, CRL, Charles River Laboratories, LEAP, Entrepreneurship, OK, ATUM, Chemistry, CDMO, Safety, CHO, CGMP, Organization, Portable, Control, IND, CMC, Partnership, Pharmaceutical industry

The collaboration is designed to enable a swift transition from pre-clinical stages directly to human clinical trials.

Key Points: 
  • The collaboration is designed to enable a swift transition from pre-clinical stages directly to human clinical trials.
  • Combining Charles River's industry-leading experience in antibody discovery services, safety, and analytics with Wheeler's Portable CMC® platform will accelerate therapeutic discovery to Investigational New Drug (IND) submission timelines.
  • Wheeler Bio's mission is to solve translational challenges inherent in advancing from discovery to CMC development and early-clinical trial material supply.
  • Jesse McCool, CEO and Co-Founder of Wheeler Bio, stated, "Wheeler is excited to expand our relationship with Charles River and to link with their discovery organization.

Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance

Retrieved on: 
Wednesday, February 14, 2024
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, Acquisition, CRL, Drug development, Charles River Laboratories, Sale, Calendar, Discovery, CDMO, GAAP, DSA, RMS, Environment, Beauty salon

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2023 and provided guidance for 2024.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2023 and provided guidance for 2024.
  • For the quarter, revenue was $1.01 billion, a decrease of 7.9% from $1.10 billion in the fourth quarter of 2022.
  • Revenue for the RMS segment was $195.8 million in the fourth quarter of 2023, a decrease of 0.2% from $196.1 million in the fourth quarter of 2022.
  • In the fourth quarter of 2023, the DSA segment’s GAAP operating margin decreased to 20.2% from 22.7% in the fourth quarter of 2022.

Multiply Labs Releases Preprint Data Showing That Automated and Manual Cell Expansion Processes Are Statistically Equivalent

Retrieved on: 
Friday, January 5, 2024
Research, Pharmaceutical, Robotics, Technology, Other Manufacturing, Science, Engineering, Biotechnology, Other Technology, Manufacturing, Other Science, Health, Multimedia, FDA, Staphylococcus epidermidis, Thermo Fisher Scientific, GMP, Gene, Charles River Laboratories, Multiplication, Therapy, Automation, Cell, UCSF, Skin

This data demonstrates that automated cell therapy manufacturing outcomes (cell quantity and quality) using Multiply Labs’ proof-of-concept robotic system are statistically equivalent to that of a process performed manually.

Key Points: 
  • This data demonstrates that automated cell therapy manufacturing outcomes (cell quantity and quality) using Multiply Labs’ proof-of-concept robotic system are statistically equivalent to that of a process performed manually.
  • “This data demonstrates that manufacturers can confidently automate their existing processes for cell expansion, without making significant modifications to the process itself, effectively minimizing bioprocess and regulatory risks.
  • In addition to cell count and viability successes, none of the robotic cell expansion samples were contaminated.
  • The research, titled “Development of a robotic cluster for automated and scalable cell therapy manufacturing,” is currently under review.

Ability Biologics Unveils Discovery Platform that Generates Antibodies with Unparalleled Specificity and Selectivity

Retrieved on: 
Wednesday, December 6, 2023
Stem Cells, Biotechnology, Health, Artificial Intelligence, Health Technology, Technology, Genetics, Other Health, Engineering, Tissue, Artificial intelligence, CFA, Investment, Charles River Laboratories, Laboratory, FTQ, Therapy, Drug discovery, Private equity, Partnership, Antibody, AI, Fonds, Cell, Temperature, Drug development, Immunoglobulin G, Pharmaceutical industry, Fine chemical, Ability

Ability Biologics (“Ability” or “the company”) announced the closing of its $12 million (US) financing round led by founding investor Amplitude Ventures .

Key Points: 
  • Ability Biologics (“Ability” or “the company”) announced the closing of its $12 million (US) financing round led by founding investor Amplitude Ventures .
  • Ability Biologics will use its AbiLeap™ discovery engine to systematically generate logic-enabled antibodies with the potential to become best-in-class or first-in-class therapeutics.
  • Their vision is to create the next generation of antibodies using powerful computational tools through its unique, proprietary AI platform.
  • Ability is establishing its laboratories in Montreal, which is emerging as a fast-paced R&D hub in key areas such as biologics, antibodies, and AI.

In Vitro Toxicology Testing Market Worth $17.1 billion | MarketsandMarkets

Retrieved on: 
Friday, October 27, 2023
MEA, Creative Biolabs, Eurofins Scientific, Pharmacology, Promega, Catalent, Patent, Intertek, Islamic finance products, services and contracts, Food, Charles River Laboratories, LATAM, Toxicology, Genetics, Absorption, Acquisition, Tissue engineering, Maintenance, Research, Protein, Phototoxicity, Software, Metabolism, Drug development, SGS, Growth, Thermo Fisher Scientific, Marketing, Merck Group, Agilent Technologies, Animal, Gene, Corrosion, Safety, Investment, Labcorp, Toxicity, Chemical safety, ADME, Medical device, Pharmaceutical industry, Fine chemical

By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services.

Key Points: 
  • By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services.
  • In 2022, the ADME segment accounted for the largest share of the in vitro toxicology testing market.
  • The pharmaceutical & biopharmaceutical segment accounted for the largest share of the industry segment in the in vitro toxicology testing market in 2022.
  • In 2022, the pharmaceutical & biopharmaceutical industry segment accounted for the largest share of the in vitro toxicology testing market.

In Vitro Toxicology Testing Market Worth $17.1 billion | MarketsandMarkets

Retrieved on: 
Friday, October 27, 2023
MEA, Creative Biolabs, Eurofins Scientific, Pharmacology, Promega, Catalent, Patent, Intertek, Islamic finance products, services and contracts, Food, Charles River Laboratories, LATAM, Toxicology, Genetics, Absorption, Acquisition, Tissue engineering, Maintenance, Research, Protein, Phototoxicity, Software, Metabolism, Drug development, SGS, Growth, Thermo Fisher Scientific, Marketing, Merck Group, Agilent Technologies, Animal, Gene, Corrosion, Safety, Investment, Labcorp, Toxicity, Chemical safety, ADME, Medical device, Pharmaceutical industry, Fine chemical

By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services.

Key Points: 
  • By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services.
  • In 2022, the ADME segment accounted for the largest share of the in vitro toxicology testing market.
  • The pharmaceutical & biopharmaceutical segment accounted for the largest share of the industry segment in the in vitro toxicology testing market in 2022.
  • In 2022, the pharmaceutical & biopharmaceutical industry segment accounted for the largest share of the in vitro toxicology testing market.

United States Clinical Trials Support Services Markets, 2023-2028 with Charles River Laboratories, IQVIA, Icon, Labcorp Drug Development, and Syneos Health Dominating - ResearchAndMarkets.com

Retrieved on: 
Friday, October 20, 2023
Health, Clinical Trials, Incidence, III, Syneos Health, Charles River Laboratories, ICON PLC, II, Prevalence, Conditional sentence, Research, Phase, Growth, Clinical trial, Labcorp Drug Development, Cancer, Patient, Pharmaceutical industry

The "US Clinical Trials Support Services Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Clinical Trials Support Services Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The demand for clinical trial support services is witnessing a significant upswing, driven by various factors such as a surge in research and development activities, a high prevalence of chronic diseases, and the increasing adoption of clinical trial support services.
  • Prominent companies dominating the US clinical trial support services market include Charles River Laboratories, IQVIA Inc, Icon plc, Labcorp Drug Development, and Syneos Health.
  • The report offers an in-depth analysis of the current market dynamics for the US clinical trial support services market from 2023 to 2028.

The Global In Vitro Toxicology Testing Market is Poised for Exponential Growth and is Expected to Reach USD 64,094.9 Million by 2030 | Infinium Global Research

Retrieved on: 
Thursday, October 12, 2023
Investment, Charles River Laboratories, Thermo Fisher Scientific, Molecular imaging, Government, Compound annual growth rate, Organization, USD, Safety, Movement, SGS, Abbott Laboratories, Perceived organizational support, Growth, Cosmetics, Toxicology, Merck Group, Eurofins Scientific, Agilent Technologies, Research, Medical device, Pharmaceutical industry

The in vitro toxicology testing market has been experiencing remarkable growth in recent years.

Key Points: 
  • The in vitro toxicology testing market has been experiencing remarkable growth in recent years.
  • The increasing demand for toxicology testing products propels the growth of the in vitro toxicology testing market.
  • Nonetheless, technological advancements in in vitro toxicology testing products create opportunities for companies operating in the market.
  • The global in vitro toxicology testing market is primed for substantial growth, driven by increasing government support, rising demand for toxicology testing products, and technological advancements.